BioSignia Announces Agreement to Deliver Chronic Disease Prediction Technology Through Regional Pharmacy Chain Kerr Drug
BioSignia, a leading preventative healthcare technology company, today announced the signing of a licensing agreement with regional pharmacy chain Kerr Drug. BioSignia’s health risk assessment (HRA) engine significantly improves prevention and management of chronic diseases by focusing on individualized disease risk assessment (DRA).
View full press release